Skip to main content Back to Top
Advertisement

11/15/2022

Leucovorin Calcium Injection

Products Affected - Description

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 1 count, NDC 63323-0631-10
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0710-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0711-00
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9554-01
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 00143-9553-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Hikma, 350 mg, vial, 1 count, NDC 00143-9552-01
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 100 mg, vial, 10 count, NDC 25021-0814-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 350 mg, vial, 1 count, NDC 25021-0816-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0828-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Sagent, 50 mg, vial, 10 count, NDC 25021-0813-10
    • Leucovorin Calcium, Teva, 100 mg, vial, 1 count, NDC 00703-5140-01 - discontinued
    • Leucovorin Calcium, Teva, 350 mg, vial, 1 count, NDC 00703-5145-01 - discontinued

Reason for the Shortage

    • Fresenius Kabi had leucovorin on shortage due to manufacturing delays and increased demand.
    • Hikma has leucovorin on shortage due to increased demand.
    • Mylan Institutional has leucovorin on shortage due to increased demand.
    • Sagent has leucovorin on shortage due to manufacturing delays.
    • Teva has discontinued leucovorin injection.

Available Products

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 50 mL vial, 1 count, NDC 63323-0631-50
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 50 mg, vial, 1 count, NDC 00143-9555-01
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 200 mg, vial, 1 count, NDC 67457-0529-20
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 350 mg, vial, 1 count, NDC 67457-0530-35
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional (Viatris), 50 mg, vial, 1 count, NDC 67457-0528-10
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 200 mg, vial, 1 count, NDC 25021-0815-30

Estimated Resupply Dates

    • Fresenius Kabi has leucovorin 200 mg and 500 mg vials on back order and the company estimates a release date of late-November to early-December 2022 for the 200 mg vials and late-November 2022 for the 500 mg vials. The 10 mg/mL 10 mL vials are on back order and the company estimates a release date of mid- to late-December 2022.
    • Hikma has leucovorin 100 mg vials and 350 mg vials on allocation. The 200 mg vials are on back order and the company estimates a release date of late-November to early-December 2022.
    • Sagent has leucovorin 100 mg and 350 mg vials on allocation. The 200 mg and 500 mg vials are on back order and the company estimates a release date of November 2022. There are short-dated 50 mg vials with an expiration date of January 2023.

Updated

Updated November 15, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 6, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.